Trigger Time in Advanced Maternal Age Patients With Low AMH (NCT03740880) | Clinical Trial Compass
TerminatedNot Applicable
Trigger Time in Advanced Maternal Age Patients With Low AMH
Stopped: insufficient data
United Arab Emirates1 participantsStarted 2019-01-07
Plain-language summary
The investigators want to verify if advanced maternal age patients with a low Anti-Müllerian hormone (AMH) level may benefit from an early trigger time (compared to a late trigger).
Who can participate
Age range
40 Years – 48 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* • POR defined according to the Bologna criteria:
* AMA: ≥40 years and AMH \<1.1 ng/ml
* Previous poor ovarian response with maximum 3 cumulus oocyte complexes retrieved after conventional stimulation
* Antral follicle count \< 5-7
* Cycling patients
* Fresh ejaculates
* ICSI
* BMI 19-32 kg/m2
* Ovarian stimulation protocol: Antagonist HMG 450 IU to ensure all receptors are covered and to ensure maximum recruitment. Dose adjustments can be made after 5 days of stimulation
* Type of trigger for final oocyte maturation: dual trigger: 10.000 IU hCG i.m. and 0.3 mg Deca
* Couples requesting preimplantation genetic testing (for aneuploidies) of their embryos
* Follicular measurements should be performed at IVI RMA Fertility, Abu Dhabi, UAE: a single operator will perform the ultrasound for the final measurement before trigger. Recruitment can be done by all physicians
* Only patients with an oral contraceptive pill (OCP) pretreatment to synchronize follicular development:
* 2 weeks OCP followed by
* a wash out of 5 days (without OCP) followed by
* o start stimulation
* Basal hormone profile (FSH, LH, E2, P4) measured between day 1-3 at IVIRMA Fertility, Abu Dhabi, UAE
* FSH \<15 IU
* E2 \<50 pg/ml
* P \<1ng/ml
* Only the Arab population
* Oocyte retrieval: 36 hours after trigger
* PGT-A
Exclusion Criteria:
* If follicular measurement before randomization shows a leading follicle ≥ 1…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.